HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

The results are published in Nature Medicine. In the Phase I trial involving 40 patients, the research group investigated the ...

This Phase III trial is based on a Phase I trial of patients in which the engineered cells were shown to be safe and effective, with minimal side effects. Initial study results were published April 9 ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

In the study, "Disease diagnostics using machine learning of B cell and T cell receptor sequences," published in Science, researchers analyzed BCR heavy chain and TCR beta chain sequences from 593 ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Following the insolvency filing, Medigene AG is exempt from the obligation to convene an extraordinary shareholder meeting according to § 92 German Stock Corporation Act (AktG).

Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...